No letup in M&A, says Shire's Ornskov
This article was originally published in Scrip
Executive Summary
"When you run out of innovation, efficiency-driven M&A is always attractive," according to Shire CEO Dr Fleming Ornskov, speaking at the annual FT Global Pharmaceuticals and Biotechnology Conference in London(17-18 November) on what is driving the M&A hoopla of 2014. A subtle swipe at former suitor AbbVie?
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.